Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Conditions
Interventions
Anlotinib
Placebo capsule
Locations
13
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing chest hospital，capital medical university
Beijing, Beijing Municipality, China
Xinqiao Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Hunan Province Tumor Hospital
Changsha, Hunan, China
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Jilin province tumor hospital
Changchun, Jilin, China
Start Date
August 1, 2013
Primary Completion Date
March 1, 2015
Completion Date
October 1, 2015
Last Updated
October 28, 2015
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions